Mandate

VINGE ADVISES CARNEGIE IN CONNECTION WITH HANSA MEDICAL’S RIGHTS ISSUE AND BLOCK SALE OF FARSTORPS GÅRD’S SHARES

March 09, 2015

Hansa Medical has resolved to carry out a rights issue of MSEK 246 before deduction of issue related costs. The rights issue is fully guaranteed through subscription undertakings and underwriting. The proceeds from the issue will be used to finance the company’s future research and development activities. In connection herewith, the company also announced that Hansa Medical’s former majority shareholder, Farstorps Gård, has sold some of its holding to certain Swedish and international institutional owners.

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes.. The company’s shares are admitted to trading on Nasdaq First North in Stockholm.

Vinge advised Carnegie which is the financial adviser in connection with the rights issue and sale. The team consists of Peter Bäärnhielm, Dain Nevonen and Sabina Börjesson.   

Related

Vinge advises Consolid Equity in connection with the establishment of Petra Group

Vinge has advised Consolid Equity Investment AB ("Consolid Equity") on the acquisition of Ström & Gulliksson, one of the leading patent agencies in the Nordics. The acquisition forms part of the establishment of Petra Group, a European platform aimed at consolidating patent agencies across Europe to combine expertise and resources primarily within patents and trademarks. Consolid acts as a strategic partner in the new group.
July 08, 2026

Vinge has advised Scandic on new credit facilities with SEK 7.5 billion credit facilities

Vinge has represented Scandic Hotels Group AB (publ) in connection with a facilities agreement for SEK 7,500,000,000 with a syndicate of banks, arranged by DNB Carnegie Investment Bank AB and Nordea Bank Abp, filial i Sverige.
July 08, 2026

Vinge has advised Vitamin Well and its majority shareholders Cinven, Bridgepoint and the founders on Vitamin Well's combination with EMPWR

Vinge has advised Vitamin Well and its majority shareholders Cinven, the founders of Vitamin Well and Bridgepoint on Vitamin Well's acquisition of EMPWR Nutrition Group from majority seller Waterland Private Equity Investments.
July 03, 2026